Last updated on August 2018

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)


Brief description of study

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Clinical Study Identifier: NCT02975336

Contact Investigators or Research Sites near you

Start Over

Carlo Salvarani

Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
Reggio Emilia, Italy
  Connect »